

Consiglio Nazionale delle Ricerche National Research Council


## Immune system on chip: Modelling and measuring the IS under the microscope.

Francesca Romana Bertani, <u>Luca Businaro</u>, Adele De Ninno, Annamaria Gerardino




Reversed

#### In the beginning we were Lithographers










#### **Lithography for Microfluidics**






#### **Lithography for Microfluidics**


Microfluidics deals with the **behaviour**, **precise control** and **manipulation** of fluids that are geometrically constrained to a small, typically **sub-millimeter**, **scale**.

Typically, micro means one of the following features:

- small volumes (μL, nL, pL, fL)
- small size
- low energy consumption
- effects of the microdomain










#### OOC: a way to include human IS specificity






"You have to remember that a worm, with very few exceptions, is not a human being"

Prof. F. Frankenstein



#### Microfluidcs for Organs-On-Chip & Micro Physiological Systems





#### **Definitions**

Microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine


An Organ-on-Chip (OoC) is a fit for purpose fabricated microfluidic-based device, containing living engineered organ substructures in a controlled micro- or nanoenvironment, that recapitulate one or more aspects of the dynamics, functionality and (patho)physiological response of an organ in vivo, in real-time monitoring mode



#### **OoC** classification

#### OoC can be classified into 2 distinct types

**Single-organ systems**: emulating key functions of single tissues or organs



**Reconstituting Organ-Level Lung Functions on a Chip** 

Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Science 328, 2010.




#### **OoC** classification

#### OoC can be classified into 2 distinct types


 Multi-organ systems: combining multiple organ/OoC to reproduce the systemic interactions that occur in

vivo.





#### **Science Fiction? Look at Tissue Chip Project**





Start:	2012
Status	active
funding	>100M\$
Partners	11
Approach	Annual awards
subprojects	>60

https://www.youtube.com/watch?v=zVIEr8c-OJk&feature=youtu.be



#### **US scenario: Meet the chips**

Meet Chip: Brain

▶ Meet Chip: Gastrointestinal System

Meet Chip: Heart

▶ Meet Chip: Female Reproductive

**System** 

Meet Chip: Muscle

► Meet Chip: Blood Vessels

Meet Chip: Lungs

► Meet Chip: Fat (Adipose)

Meet Chip: Liver

Meet Chip: Skin


Meet Chip: Kidneys

▶ Meet Chip: Disease Models

https://ncats.nih.gov/tissuechip/chip

#### Tiny Organs in Orbit






Concept of Planar BBB Neuro Vascular Unit Chip (Vanderbilt)




#### **US scenario: Companies**















https://vimeo.com/398591225










https://www.aimbiotech.com/videos.html





#### **EU Scenario - Companies**




















#### Organs on chip companies



# Microfluidics for Immuno-Oncology Recreating and Measuring cells battle in the tumor ecosystem




**TIFN** 

Istituto di Fotonica e Nanotecnologie - Institute for Photonics and Nanotechnologies

Consiglio Nazionale delle Ricerche National Research Council

### Lab on a Chip

Miniaturisation for chemistry, physics, biology, materials science and bioengineering



**RSC** Publishing


Luca Businaro, Fabrizio Mattei et al.
Cross talk between cancer and immune cells: exploring complex dynamics in a microfludic environment



Chemotherapy-induce immune response and genetic mutations

Drug-resistance tumor heterogeneous microenvironments

Immunotherapeutic strategies






Chemotherapy-induce immune response and genetic mutations

Drug-resistance tumor heterogeneous microenvironments


Immunotherapeutic strategies






- Chemotherapy-induce immune response and genetic mutations
- Drug-resistance tumor heterogeneous microenvironments

Immunotherapeutic strategies





- Chemotherapy-induce immune response and genetic mutations
- Drug-resistance tumor heterogeneous microenvironments
- Immunotherapeutic strategies








#### How dying tumor cells get noticed

#### Chemotherapy-induced anticancer immune response




Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Erika Vacchelli<sup>†</sup>, Yuting Ma<sup>†</sup>, Elisa E. Baracco, Antonella Sistigu, David P. Enot, Federico Pietrocola, Heng Yang, Sandy Adjemian, Kariman Chaba, Michaela Semeraro, Michele Signore, Adele De Ninno, Valeria Lucarini, Francesca Peschiaroli, Luca Businaro, Annamaria Gerardino, Gwenola Manic, Thomas Ulas<sup>13</sup>, Patrick Günther, Joachim Schultze, Aicha Goubar, Gautier Stoll, Céline Lefebvre, Sylvie Rusakiewicz, Sylvain Ladoire, Monica Lucattelli, Fabrice André, Lorenzo Galluzzi, Ilio Vitale, Giovanna Schiavoni, Fabrizio Mattei<sup>\*</sup>, **Laurence Zitvogel<sup>\*</sup>, & Guido Kroemer<sup>\*</sup>· Science** 2015.





- Major finding: Anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1)
- Mechanism: FPR1 and its ligand ANXA1 mediate stable contacts between dendritic cells and dying cancer cells. In mice cancer cells growing in Fpr1—/— hosts were resistant to anthracyclines. Failure of DCs lacking FPR1 to approach.
- Impact: Breast or colon cancer patients expressing a variant of FPR1 and treated withanthracyclines showed poor metastasisfree and overall survival

#### 2D COCULTURE CHIP: ADHERENT AND FLOATING CELLS












front.




MOTILITY AND INTERACTION PARAMETERS




Vacchelli et al., Science, 2015 Businaro, De Ninno et al., Lab chip, 2014 De Ninno et al, Meth in Enzimatology 2019











Only DCs isolated from the pool of PBMCs don't migrate toward dying cancer cells






Stable conjugates between dying tumor cells and human DCs prolonged (> 60 min) juxtaposition




Interaction times between dying cancer cells and immune cells





Vacchelli et al., Science 2015


#### **Tracking patterns of human immune cells toward apototic target**















#### 3D CANCER-IMMUNE MODEL ON CHIP FOR IMMUNOTHERAPIC APPROACHES


Consiglio Nazionale delle Ricerche National Research Council








Racioppi et al., Nat Comm 2019 De Ninno et al., Met in Enzimology 2019 Parlato et al., Sc Reports 2017 Lucarini et al., JID 2017


















IFN-DC sense environmental signals and adjust their motion towards


cancer cells undergoing RI-induced apoptosis







#### Motility in 2D and 3D




Clearing the Dead Confocal optical sections of IFN DCs in RI tumor site interval time 30min IFN DC FITC RI -SW620 RFP ху yz IFN DC FITC RI -SW620 RFP ΧZ f drug treated cancer cells: 3D reconstruction of Z-stacks confocal laser scanning \_IFN DC engulfment ability

## Tor Vergata Sensors Group


#### Automated tracking Cell Hunter software:


Measuring un-labeled cancer-immune interactions in multi-cell type context


#### Cancer and immune cell centre discrimination



MC Comes et al. Scientific reports 2019 MC Comes et al. IEEE TNNLS *submitted* Agliari et al. Scientific reports 2018










#### **Towards in-silico staining**

#### **Very Preliminary data!!**






Unpublished: curtesy of CNR-IAC (Roberto Natalini, Gabriella Bretti, Elishan Brown, Paola Stolfi, Davide Vergni




#### Towards in-silico /on-chip experiment merging





Unpublished: curtesy of CNR-IAC (Roberto Natalini, Gabriella Bretti, Elishan Brown, Paola Stolfi, Davide Vergni









#### **Synergy with Systems Biology**

Age and Development Health **Across the Population**  iScience 23, 101509, September 25, 2020 The Whole Body as the System in Systems Immunology


Maya M.L. Poon<sup>1,2</sup> and Donna L. Farber<sup>1,2,3,\*</sup>








Andreas Bergthaler Nat Immunology 2017




Immune Cell Computation



Cohen Front. Immun 2019



Organs on chip, imaging and computation for biological discovery





ORGANS ON CHIPS IN SPACE

 $\dot{x} = \begin{bmatrix} 0 & 1 \\ -2 & -3 \end{bmatrix} x + \begin{bmatrix} 1 \\ 1 \end{bmatrix} u(t)$ 

$$\iota(t) = 0$$

$$\begin{bmatrix} 1 \\ -3 \end{bmatrix} \begin{bmatrix} x_{1e} \\ x_{2e} \end{bmatrix} = 0 \Rightarrow \begin{bmatrix} x_{1e} \\ x_{2e} \end{bmatrix} = \begin{bmatrix} 0 \\ 0 \end{bmatrix}$$

Science

2018
BREAKTHROUGH
of the YEAR





Take a look!!



Editorial Overview

Seeing Your Way to New Insights in Biology ★

Charles Reilly <sup>1</sup> <sup>△</sup> <sup>∞</sup>, Donald E. Ingber <sup>1, 2, 3</sup>

**⊞ Show more** 

https://doi.org/10.1016/j.jmb.2019.04.033



#### Thanks to:



Gut on chip Liver On Chip



Tumor microenvironment reconstitution



Organoids, Immunotherapy



**Immunosurvelliance** 



Statistical Mechanics
& Biological
Complexity





In-silico models



Contacts: luca.businaro@cnr.it adeledeninno@gmail.com